References

Papers

- Evaluation of Escherichia coli Membrane Preparations of Canine CYP1A1, CYP2B11, 2C21, 2C41, 2D15, 3A12 and 3A26 with Coexpressed Canine Cytochrome P450 Reductase.
  C. W. Locuson, B. T. Ethell, M. W. Voice, D. Lee & K. L. Feenstra
  (Pfizer Animal Health, Veterinary Medicine Research & Development, Metabolism & Safety, Kalamazoo, Michigan, USA; Pfizer Global Research & Development Pharmacokinetics, Dynamics & Metabolism, Sandwich, Kent, UK; Cypex Ltd, Dundee, UK; Advantagen Ltd, Dundee, UK)

- N. L. Meyers & R. I. Hickling
  (Alizyme Therapeutics Ltd, Cambridge, UK)

- T. Takanohashi, T. Koizumi, R. Mihara & “K. Okudaira
  (Pharmaceutical Company, Ajinomoto Co., Inc., Kawasaki, Japan; “Faculty of Pharmaceutical Sciences, Toho University, Chiba, Japan)
  Drug Metabolism & Pharmacokinetics (2007)
  Vol 22 (6), p409 - 418
  Silybin is Metabolized by Cytochrome P450 2C8 in vitro.

  (Palacky University at Olomouc, Olomouc, Czech Republic)
  Drug Metabolism & Disposition (2007), Vol 35 (11), p2035 - 2039
  Sulfamethoxazole and its Metabolite Nitroso Sulfamethoxasole Stimulate Dendritic Cell Costimulatory Signaling.

  (Department of Pharmacology & Therapeutics, University of Liverpool, Liverpool, UK. GlaxoSmithKline, Drug Metabolism & Pharmacokinetics, Ware, Herts, UK. Dept Medicine, University of Western Ontario, London, Ontario, Canada.)
  Journal of Immunology (2007), Vol 178, p5533 - 5542
  (Details use of Bactosomes for time dependent inhibition studies)
  The Metabolism of the 5HT3 Antagonists Ondansetron, Alosetron and GR87442 I: A comparison of in vitro and in vivo Metabolism and in vitro Enzyme Kinetics in Rat, Dog and Human Hepatocytes, Microsomes and Recombinat Human Enzymes.

- G. I. Somers, A. J. Harris, M. K. Bayliss & J. B. Houston
  (RI CEDD DMPK, GSK, Stevenage, UK. Psychiatry CEDD DMPK, GSK, Harlow, UK. University of Manchester, UK)
  Xenobiotica (2007), Vol 37 (8), p832 - 854
  Study on the Cytochrome P450 Mediated Oxidative Metabolism of the Terpene Alcohol Linalool: Indication of Biological Epoxidation.

- R. J. W. Meesters, M. Duise & J. Hollender
Pharmacokinetic Consequences of Time-Dependent Inhibition using the Isolated Perfused Rat Liver Model.

J.R. Kenny & K. Grime
(Department of Physical & Metabolic Sciences, AstraZeneca R & D, Charnwood, Loughborough, Leicestershire, UK)
Comparative Analysis of Substrate & Inhibitor Interactions with CYP3A4 and CYP3A5.

M. G. Soars, K. Grime & R. J. Riley
(Department of Physical & Metabolic Science, AstraZeneca R & D, Charnwood, Loughborough, Leicestershire, UK)

D. McGinnity, J. Tucker, S. Trigg & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom)
Drug Metabolism & Disposition (2005), Vol 33, No. 11, p1700 - 1707
Automated Assessment of Time-Dependent Inhibition of Human Cytochrome P450 Enzymes Using Liquid Chromatography-Tandem Mass Spectrometry Analysis.

A. Atkinson, J. R. Kenny & K. Grime
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom)
Drug Metabolism & Disposition (2005), Vol 33, No. 11, p1637 - 11647
Pre-clinical Assessment of DRF 4367, a Novel COX-2 Inhibitor: Evaluation of Pharmacokinetics, Absolute Oral Bioavailability and Metabolism in Mice and Comparative Inter-species in vitro Metabolism.

(Drug Metabolism & Pharmacokinetics, Discovery Research, Dr Reddy's Laboratories Ltd, Miyapur, Hyderabad, India)
Metabolism of D3-Carene by Human Cytochrome P450 Enzymes: Identification and Characterisation of Two New Metabolites.

M. Duisken, D. Benz, T. H. Peiffer, B. Blömeke & J. Hollender
(Institute of Hygiene and Environmental Medicine, RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany)
Current Drug Metabolism (2005), Vol 6, p593 - 601
Metabolism of 1,8-Cineole by Human Cytochrome P450 Enzymes: Identification of a New Hydroxylated Metabolite.

M. Duisken, F. Sandner, B. Blömeke & J. Hollender
(Institute of Hygiene and Environmental Medicine, RWTH Aachen, Pauwelsstraße 30, 52074 Aachen, Germany)
Biochimica et Biophysica Acta (2005), Vol 1722, p304 - 311
Cytochrome P450-mediated Oxidation of Glucuronide Derivatives: Example of Estradiol-17b-glucuronide Oxidation to 2-hydroxy-estradiol-17b-glucuronide by CYP2C8.

M. Delaforge, A. Pruvost, L. Perrin & F. André

R. Weaver, K. S. Graham, I. G. Beattie & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom)
Drug Metabolism & Disposition (2003), Vol 31, No. 37, p955 - 966
A Comparison of Relative Abundance, Activity Factor and Inhibitory Monoclonal Antibody Approaches in the Characterization of Human CYP Enzymology.

M. G. Soars, H. V. Gelboin*, K. W. Krausz* & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom and * Laboratory of Molecular Carcinogenesis, National Cancer Institute, NIH, Bethesda, MD, USA)
British Journal of Clinical Pharmacology (2003), Vol 55, p175 - 181

(Wyeth-Ayerst Research, Princeton, New Jersey, USA)
Drug Metabolism & Disposition (2001), Vol 29, No. 1, p23 - 29
Predicting Drug Pharmacokinetics in Humans from in vitro Metabolism Studies.

D. F. McGinnity & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom)
Automated Definition of the Enzymology of Drug Oxidation by the Major Human Drug Metabolizing Cytochrome P450s.

(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom)
Drug Metabolism & Disposition (2000), Vol 28, No. 11, p1327 - 1334
Fully Automated Analysis of Activities Catalysed by the Major Human Liver Cytochrome P450 (CYP) Enzymes: Assessment of Human CYP Inhibition Potential.

G. C. Moody, S. J. Griffin, A. N. Mather, D. F. McGinnity & R. J. Riley
(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom)
Xenobiotica (1999), Vol 229, No. 1, p53 - 75
Rapid Characterisation of the Major Drug-metabolising Human Hepatic Cytochrome P450 Enzymes Expressed in Escherichia Coli.

(AstraZeneca R&D Charnwood, Loughborough, Leicestershire, United Kingdom and * Biomedical Research Centre, University of Dundee, Ninewells Hospital, Dundee, UK)
Drug Metabolism & Disposition (1999), Vol 27, No. 9, p1017 - 1023

Posters

A Comparison of Cytochrome P450 Activities in Bactosomes, Supersomes, and Human Liver Microsomes
K. Settle, A. Madan, B Ogilvie, P. Carroll, A. Hussain & A. Parkinson
Validation of E. coli-expressed P450 Enzymes for Inhibition Screening.
M.A. Taylor, A. Patel, J.C. Bloomer & S.E. Clarke

Mechanism & Extrapolation Technologies Dept., DMPK, GlaxoSmithKline, The Frythe, Welwyn, Herts, AL6 9AR, UK
Presented at DMDG 2002, Durham, UK

Cocktail Analysis of CYP Inhibition Using MS/MRM Technology and Recombinant Proteins.
R. Weaver, K. S. Graham, I. G. Beattie & R. J. Riley
Physical & Metabolic Sciences, AstraZeneca R & D Charnwood, Bakewell Road, Loughborough, LE11 5RH, UK
Presented at ISSX 2002, Orlando, USA (Abstract No. 359)

A Comparison of Human Liver Microsomes, Bactosomes and Supersomes for Cytochrome P450 Inhibition Studies
A. Hussain, B Ogilvie & A. Parkinson
XenoTech LLC, 16825 West 116th Street, Lenexa, Kansas 66219, USA
Presented at ISSX 2002, Orlando, USA (Abstract No. 424)

Automated Cytochrome P450 Inhibition Screening.
G. N. Hallam, G. T. Webber & S. G. Wood
BioDynamics Research Ltd, Rushden, Northamptonshire, UK
Presented at 18th European Workshop on Drug Metabolism 2002, Valencia

Recombinant Human CYP1A2 Catalyses the O-demethylation of 7-methoxycoumarin.
S.W. Ayivor, J. Baird & M. Pritchard
Cypex Ltd
Presented at ISSX 2002, Orlando, USA (Abstract No. 91)

Determination of 3,5-diacetyl-1,4-dihydrolutidine Using HPLC with Fluorometric Detection.
J. Baird & M. Pritchard
Cypex Ltd
Presented at ISSX 2002, Orlando, USA (Abstract No. 314)

Enzymatic production of drug metabolites using recombinant human cytochrome P450s.
M. Voice
Cypex Ltd
Presented at RSC DMG 2002, Edinburgh, UK

Determination of 4-methylumbelliferone UGT activity by HPLC with Fluorometric Detection and Application to the Study of Human UGT1A6 Expressed in Escherichia coli.
S. Ayivor & M. Pritchard
Cypex Ltd
Presented at ISSX 2003, Dijon, France (Abstract No. 118)

Determination of 4-methylumbelliferone Sulfotransferase 1A1*1 activity using HPLC with Fluorometric Detection.
J. Baird, M. Pritchard & M. Voice
Cypex Ltd
Presented at ISSX 2003, Providence, Rhode Island USA (Abstract No. 395)
Automated Cytochrome P450 Profiling.
E. N. Gao, R. H. Smith, B. Li, M. C. Secosky, J. W. Gross & A. J. Pope
GlaxoSmithKline, Upper Providence, Pennsylvania, 19426, USA
Presented at SBS 2004

Effects of common organic solvents on the activity of recombinant human cytochrome P450s expressed in E. coli.
J. Baird, C. Begg, M. Pritchard & M. Voice
Cypex Ltd
Presented at ISSX/JSSX 2005, Maui, Hawaii, USA (Abstract No. 587)

An investigation into the use of 4-methylumbelliferone, p-nitrophenol and 1-naphthol as substrates for recombinant human SULT1B1 expressed in E. coli.
G. Macintyre, M. Pritchard & M. Voice
Cypex Ltd
Presented at ISSX/JSSX 2005, Maui, Hawaii, USA (Abstract No. 731)

An Inter-laboratory Analysis of Nortryptyline CYP interactions in vitro Confirms Merits of fuinc Considerations.
P. Roberts, R. J. Riley, R. Swan, D. Slee & M. Whittaker
School of Pharmaceutical Science, University of Central Lancashire, Preston, UK
Presented at ISSX 2006, Manchester, UK (Abstract No. 125)

CYP2D-synthesized Dopamine in the Brain. The effect of Psychotropics.
E. Bromek, A. Haduch & W. A. Daniel
Institute of Pharmacology, Polish Academy of Sciences, Krakow, Poland
Presented at MDO 2008, Saratoga Springs, USA (Abstract No. 66)